Increased serum levels of IL-17A and Th17 cells in MS patients has been reported, ranging from 0.77 to 2.48 and 0.34 to 1.55% of total CD4+ T cells in MS patients compared to healthy controls, respectively (96). This evidence concerns the gene IL17A and myeloid sarcoma.